MCLA 128

Drug Profile

MCLA 128

Alternative Names: MCLA-128

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merus
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 19 Sep 2017 Merus plans a phase II trial for Breast cancer (Metastatic disease, Late-stage disease, Combination therapy, Chemotherapy-induced, Second-line therapy or greater) in USA and Europe in fourth quarter of 2017 (NCT03321981) (EudraCT2017-002821-39)
  • 19 Sep 2017 Merus has patent protection for Biclonics® technology in USA
  • 22 Aug 2017 Merus has patent protection for Biclonics® technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top